Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2004-12-01
2008-10-07
Chen, Stacy B (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C530S326000, C424S209100
Reexamination Certificate
active
07432045
ABSTRACT:
This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
REFERENCES:
patent: 4795740 (1989-01-01), Cohen et al.
patent: 5104854 (1992-04-01), Schlesinger et al.
patent: 5182265 (1993-01-01), Bruzzese et al.
patent: 5260420 (1993-11-01), Burnouf-Radosevich et al.
patent: 5380727 (1995-01-01), Dëziel et al.
patent: 5441936 (1995-08-01), Houghten et al.
patent: 5645849 (1997-07-01), Pruss et al.
patent: 5700780 (1997-12-01), Beaulieu et al.
patent: 5877282 (1999-03-01), Nadler et al.
patent: 0 531 080 (1993-03-01), None
patent: 2739621 (1997-04-01), None
patent: 4-21635 (1992-01-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/64449 (1999-12-01), None
patent: WO 01/57072 (2001-08-01), None
patent: WO 01/57072 (2001-08-01), None
Jones et al. Journal of Virology, Dec. 2006, 80(24):11960-11967.
Aldrian-Herrada, G. et al., “A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons.”Nucleic Acids Res, 26: 4910-4916, 1998; Oxford University Press.
Banfield, B. W. et al., “Evidence for an interaction of herpes simplex virus chondroitin sulfate proteoglycans during infection.”Virology 208: 531-539, 1995; Academic Press, Inc.
Berkowitz, B. A. et al., “Magainins: A new family of membrane-active host defense peptides.”Biochem. Pharmacol.39: 625-629, 1990; Pergamon Press.
Böcher, B. et al., “Peptides that Block Hepatitis B Virus Assembly: Analysis by Cryomicroscopy, Mutagenesis and Transfection.”The EMBO Journal 17(23): 6839-6845, 1998; Oxford University Press.
Boulikas, T., “Nuclear Localization Signals (NLS).”Critical Reviews in Eukaryotic Gene Expression, 3(3) pp. 193-227, 1993; CRC Press, Inc.
Brandt, C. R. et al., “A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing.”J. Virol. Methods.36: 209-222, 1992; Elsevier Science Publishers B.V.
Brandt, C. R. et al., “Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.”Antimicrob. Agents Chemother.40: 1078-1084, 1996; American Society for Microbiology.
Brandt, C. R. et al., “Inhibition of HSV ocular infection by membrane transiisting peptides.”Investigative Ophthalmology and Visual Science, vol. 42, No. 4, p. S108, 2000; Association for Research in Vision and Ophthalmology; Assoc. Research Vision Opthalmology Inc.
Brugidou, J. et al., “TheRetro inversoForm of a Homeobox-Derived Short Peptide is Rapidly Internalized by Cultured Neurones: A New Basis for an Efficient Intracellular Delivery System.”Biochemical and Biophysical Research Communications 214(2): 685-693, 1995; Academic Press Inc.
Bultmann, H. et al., “Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1.”J. Virol.75: 2634-2645, 2001; American Society for Microbiology.
Bultmann, H. et al., “Peptides containing membrane-transiting motifs inhibit virus entry.”J. Biol. Chem.277: 36018-36023, 2002; The American Society for Biochemistry and Molecular Biology, Inc.
Cai, W. et al., “Role of glycoprotein B of herpes simplex virus type I in viral entry and fusion.”J. Virol.62: 2598-2604, 1988; American Society for Microbiology.
Campadelli-Fiume, G. et al., “Glycoprotein C-dependent attachment of herpes simplex virus to susceptible cells leading to productive infection.”Virology 178: 213-222, 1990.
Choudhury, I. et al., “Inhibition of HIV-1 Replication by a Test RNA-Binding Domain Peptide Analog.”Journal of Acquired Deficiency Syndromes and Human Retrovirology, vol. 17, No. 2, pp. 104-111, Feb. 1, 1998; Lippincon-Raven Publishers (Philadelphia).
Cockrell, A. S. et al., “Herpes simplex virus type 2 UL45 is a type II membrane protein.”J. Virol.72: 4430-4433, 1998; American Society for Microbiology.
Coen, D. M. et al., “Fine mapping and molecular cloning of mutations in the herpes simplex virus DNA polymerase locus.”J. Virol.49: 236-247, 1984; American Society for Microbiology.
Cohen, E. A. et al., “Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2.”Nature,321: 441-443, 1986.
Derossi, D. et al., “The third helix of the antennapedia homeodomain translocates through biological membranes”J. Biol. Chem.269: 10444-10450, 1994; The American Society for Biochemistry and Molecular Biology, Inc.
Derossi, D. et al., “Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent.”J. Biol. Chem.217: 18188-18193, 1996; The American Society for Biochemistry and Molecular Biology, Inc.
Derossi, D. et al., “Trojan peptides: the penetration system for intracellular delivery.”Trends Cell. Biol.8: 84-87, 1998; Elsevier Science Ltd.
Derossi, D., “Antennapedia Homeodomain Third Helix as a Peptide and Oligonucleotide Vector.”Restorative Neurology and Neuroscience 8: 17-18, 1995; Elsevier Science Ireland Ltd.
Desai, P. J. et al., “Excretion of non-infectious virus particles lacking gH by a temperature-sensitive mutant of herpes simplex virus type I: Evidence that gH is essential for virion infectivity.”J. Gen. Virol.69: 1147-1156, 1988; SGM (Great Britain).
Du, C. et al., “Conformational and Topological Requirements of Cell-Permeable Peptide Function.”J. Peptide Res.51: 235-243, 1998; Munksgaard.
Dutia, B. et al., “Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides.”Nature 321: 439-441, 1986.
Elliott, G. et al., “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein.”Cell 88: 223-233, 1997; Cell Press.
Fawell, S. et al., “Tat-mediated delivery of heterologous proteins into cells.”Proc. Natl. Acad. Sci. USA 91: 664-668, 1994.
Fields, C. G. et al., “HBTU activation for automated Fmoc solid-phase peptide synthesis.”Peptide Res. 4: 95-101, 1991.
Flores, E. R. et al., “Establishment of the human papillomavirus type 16 (PHV-16) life cycle in an immortalized human foreskin keratinocyte cell line.”Virology 262: 344-354, 1999; Academic Press.
Fuller, A. O. et al., “Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface.”Proc. Natl. Acad. Sci. USA 84: 5454-5458, 1987.
Fuller, A. O. et al., “Herpes simplex virus type I entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration.”J. Virol. 66: 5002-5012, 1992; American Society for Microbiology.
Gariepy, J. et al., “Vectorial delivery of macromolecules into cells using peptide-based vehicles.”Trends Biotechnol.19: 21-28, 2001; Elsevier Science Ltd.
Geraghty, R. J. et al., “Entry of alphaherpesviruses mediated by poliovirus receptor related protein 1 and poliovirus receptor.”Science 280: 1618-1620, 1998.
Gibbs, J. S. et al., “Sequence and mapping analysis of the herpes simplex virus DNA polymerase gene predicts a c-terminal substrate binding domain.”Proc. Natl. Acad. Sci. USA 82: 7969-7973, 1985.
Goldstein, D. J. et al., “Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.”Virology 166: 41-51, 1988; Academic Press, Inc.
Grau, D.
Brandt Curtis R.
Bultmann Hermann
Chen Stacy B
Foley & Lardner LLP
Wisconsin Alumni Research Foundation
LandOfFree
Method of inhibiting influenza infection with antiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting influenza infection with antiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting influenza infection with antiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3997670